Christian F. Meyer
Distinguished in Bone Tumor

Dr. Christian F. Meyer

Oncology
Johns Hopkins Medicine
Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
Offers Telehealth

Distinguished in Bone Tumor
Johns Hopkins Medicine
Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010.

Dr. Meyer is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, Fibrosarcoma, Osteosarcoma, and Salpingo-Oophorectomy.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles and participated in 1 clinical trial in the study of Bone Tumor.

Graduate Institution
Baylor College Of Medicine, PhD, 1999
Residency
University of Maryland Medical Center, Internal Medicine, 2005
Specialties
Oncology
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
Johns Hopkins University School of Medicine, Medical Oncology, 2010
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Johns Hopkins Bayview Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, Baltimore, MD 21287
Call: 410-955-8964

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2026
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma
Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Other, Radiation
Study Drug: Nivolumab
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
Enrollment Status: Completed
Publish Date: November 22, 2024
Intervention Type: Biological
Study Drug: Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody
Study Phase: Phase 1
A Phase 1B Study of Unesbulin (PTC596) in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma
A Phase 1B Study of Unesbulin (PTC596) in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma
Enrollment Status: Completed
Publish Date: March 15, 2024
Intervention Type: Drug
Study Drugs: PTC596, Dacarbazine
Study Phase: Phase 1
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma
A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: April 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: September 09, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 13 Less Clinical Trials
Similar Doctors
Daniel Lubelski
Distinguished in Bone Tumor
Dr. Daniel Lubelski
General Surgery | Oncology | Neurosurgery
Distinguished in Bone Tumor
Dr. Daniel Lubelski
General Surgery | Oncology | Neurosurgery

Johns Hopkins Outpatient Center

601 North Caroline Street, Floor 5, Floor 5, 
Baltimore, MD 
 (1.0 miles away)
410-955-6406
Languages Spoken:
English, Hebrew
See accepted insurances
Offers Telehealth

Daniel Lubelski is a fellowship-trained neurosurgeon with expertise in complex spine surgery and peripheral nerve surgery. He treats patients with spinal diseases and deformities, spine and nerve tumors, and brachial plexus injuries and other peripheral nerve injuries. Dr. Lubelski’s training in complex and robotic spine surgery, spinal oncology and peripheral nerve injuries allows him to comprehensively evaluate patients and develop custom treatment plans to address symptoms and improve patients’ quality of life. He prioritizes patient-centered care, effective communication and working in multidisciplinary collaboration to identify the best treatment. After obtaining his undergraduate degree at the City University of New York, Dr. Lubelski spent a year doing predoctoral research at the National Institutes of Health. He then obtained his medical degree from the Cleveland Clinic Lerner College of Medicine, and he performed stem cell tumor research as a Howard Hughes Medical Institute fellow. Dr. Lubelski went on to the Johns Hopkins University School of Medicine for a neurosurgery residency and an enfolded fellowship in peripheral nerve surgery. His postdoctoral training also included a fellowship in complex spine surgery and spinal oncology at Johns Hopkins, as well as a traveling fellowship with advanced training at the Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Dr. Lubelski is a prolific researcher who focuses on patient quality of life and on using big data to develop individualized prediction models to determine optimal treatments tailored to each person. He has authored more than 200 peer-reviewed papers and numerous textbook chapters, has lectured nationally and internationally, and serves as a reviewer for the top neurosurgical journals. Dr. Lubelski is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Spinal Tumor, Chordoma, Spinal Stenosis, Spinal Fusion, and Laminectomy.

Distinguished in Bone Tumor
Dr. Dennis A. Priebat
Hematology Oncology | Oncology
Distinguished in Bone Tumor
Dr. Dennis A. Priebat
Hematology Oncology | Oncology
110 Irving St Nw, Suite 2a38, 
Washington, DC 
 (33.9 miles away)
202-877-2505
Languages Spoken:
English
See accepted insurances

Dennis Priebat is a Hematologist Oncology specialist and an Oncologist in Washington, Washington, D.c.. Dr. Priebat is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Rhabdomyosarcoma Embryonal.

Distinguished in Bone Tumor
Dr. John A. Abraham
Orthopedics | Hematology | Oncology
Distinguished in Bone Tumor
Dr. John A. Abraham
Orthopedics | Hematology | Oncology
231 Granite Run Dr, 
Lancaster, PA 
 (55.6 miles away)
267-715-0700
Languages Spoken:
English
See accepted insurances

John Abraham is an Orthopedics specialist and a Hematologist in Lancaster, Pennsylvania. Dr. Abraham is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Infantile Myofibromatosis, Congenital Generalized Fibromatosis, Desmoid Tumor, Hip Replacement, and Osteotomy.

VIEW MORE BONE TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Meyer's expertise for a condition
ConditionClose
  • Elite
  • Adult Soft Tissue Sarcoma
    Dr. Meyer is
    Elite
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Fibrosarcoma
    Dr. Meyer is
    Elite
    . Learn about Fibrosarcoma.
    See more Fibrosarcoma experts
  • Rhabdomyosarcoma
    Dr. Meyer is
    Elite
    . Learn about Rhabdomyosarcoma.
    See more Rhabdomyosarcoma experts
  • Distinguished
  • Alveolar Soft Part Sarcoma
    Dr. Meyer is
    Distinguished
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Angiosarcoma
    Dr. Meyer is
    Distinguished
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Bone Tumor
    Dr. Meyer is
    Distinguished
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Chondrosarcoma
    Dr. Meyer is
    Distinguished
    . Learn about Chondrosarcoma.
    See more Chondrosarcoma experts
  • Chordoma
    Dr. Meyer is
    Distinguished
    . Learn about Chordoma.
    See more Chordoma experts
  • Desmoid Tumor
    Dr. Meyer is
    Distinguished
    . Learn about Desmoid Tumor.
    See more Desmoid Tumor experts
View All 23 Distinguished Conditions
  • Advanced
  • Adrenal Cancer
    Dr. Meyer is
    Advanced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Adrenocortical Carcinoma
    Dr. Meyer is
    Advanced
    . Learn about Adrenocortical Carcinoma.
    See more Adrenocortical Carcinoma experts
  • Angiosarcoma of the Liver
    Dr. Meyer is
    Advanced
    . Learn about Angiosarcoma of the Liver.
    See more Angiosarcoma of the Liver experts
  • Angiosarcoma of the Scalp
    Dr. Meyer is
    Advanced
    . Learn about Angiosarcoma of the Scalp.
    See more Angiosarcoma of the Scalp experts
  • Lung Cancer
    Dr. Meyer is
    Advanced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Neurofibromatosis
    Dr. Meyer is
    Advanced
    . Learn about Neurofibromatosis.
    See more Neurofibromatosis experts
View All 8 Advanced Conditions
  • Experienced
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Meyer is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Astrocytoma
    Dr. Meyer is
    Experienced
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
    Dr. Meyer is
    Experienced
    . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
    See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
  • Brain Tumor
    Dr. Meyer is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Breast Cancer
    Dr. Meyer is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Meyer is
    Experienced
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.